rs312262767
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_025137.4(SPG11):c.5470C>T(p.Arg1824*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000434 in 1,614,072 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_025137.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- hereditary spastic paraplegia 11Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Illumina, G2P
- amyotrophic lateral sclerosis type 5Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Charcot-Marie-Tooth disease axonal type 2XInheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp
- juvenile amyotrophic lateral sclerosisInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_025137.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SPG11 | NM_025137.4 | MANE Select | c.5470C>T | p.Arg1824* | stop_gained | Exon 30 of 40 | NP_079413.3 | ||
| SPG11 | NM_001411132.1 | c.5326C>T | p.Arg1776* | stop_gained | Exon 30 of 40 | NP_001398061.1 | |||
| SPG11 | NM_001160227.2 | c.5470C>T | p.Arg1824* | stop_gained | Exon 30 of 38 | NP_001153699.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| SPG11 | ENST00000261866.12 | TSL:1 MANE Select | c.5470C>T | p.Arg1824* | stop_gained | Exon 30 of 40 | ENSP00000261866.7 | ||
| SPG11 | ENST00000535302.6 | TSL:1 | c.5470C>T | p.Arg1824* | stop_gained | Exon 30 of 38 | ENSP00000445278.2 | ||
| SPG11 | ENST00000427534.6 | TSL:1 | c.5470C>T | p.Arg1824* | stop_gained | Exon 30 of 37 | ENSP00000396110.2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000795 AC: 2AN: 251418 AF XY: 0.0000147 show subpopulations
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461884Hom.: 0 Cov.: 32 AF XY: 0.00000413 AC XY: 3AN XY: 727248 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152188Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74360 show subpopulations
ClinVar
Submissions by phenotype
Hereditary spastic paraplegia 11 Pathogenic:2Other:1
This sequence change creates a premature translational stop signal (p.Arg1824*) in the SPG11 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SPG11 are known to be pathogenic (PMID: 19105190, 20110243, 22154821, 26556829). This variant is present in population databases (rs312262767, gnomAD 0.002%). This premature translational stop signal has been observed in individuals with hereditary spastic paraplegia (PMID: 19105190, 26374131). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 41324). For these reasons, this variant has been classified as Pathogenic.
not provided Pathogenic:2
The R1824X variant in the SPG11 gene has been reported previously in the presence of a second SPG11 variant in multiple unrelated individuals with features of hereditary spastic paraplegia, including mental deterioration, progressive gait disturbance, increased reflexes, and brain abnormalities including thin corpus callosum, periventricular white matter, and cortical atrophy (Denora et al., 2009; Vanderver et al., 2012; Lynch et al., 2015). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R1824X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret R1824X as a pathogenic variant.
SPG11-related disorder Pathogenic:1
The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000041324 / PMID: 19105190). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at